Objectives: The aim of this prospective phase II, randomized, investigator-blinded study (NCT00690378) was to compare the efficacy and safety of ceftazidime-avibactam and imipenem-cilastatin in hospitalized adults with serious complicated urinary tract infection (cUTI) due to Gram-negative pathogens.
Patients And Methods: Patients aged between 18 and 90 years with cUTI were enrolled and stratified by infection type (acute pyelonephritis or other cUTI) and randomized 1:1 to receive intravenous ceftazidime 500 mg plus avibactam 125 mg every 8 hours or imipenem-cilastatin 500 mg every 6 hours. Patients meeting pre-specified improvement criteria after 4 days could be switched to oral ciprofloxacin. Patients were treated for a total of 7-14 days. The primary efficacy objective was a favorable microbiological response at the test-of-cure (TOC) visit 5-9 days post-therapy in microbiologically evaluable (ME) patients.
Results: Overall, 135 patients received study therapy (safety population); 62 were included in the ME population (ceftazidime-avibactam, n = 27; imipenem-cilastatin, n = 35). The predominant uropathogen was Escherichia coli. Favorable microbiological response was achieved in 70.4% of ME patients receiving ceftazidime-avibactam and 71.4% receiving imipenem-cilastatin at the TOC visit (observed difference -1.1% [95% CI: -27.2%, 25.0%]). Among ME patients with ceftazidime-resistant uropathogens, response was observed in 6/7 (85.7%) receiving ceftazidime-avibactam. Adverse events were observed in 67.6% and 76.1% of patients receiving ceftazidime-avibactam and imipenem-cilastatin, respectively. Limitations of the study include the small number of patients in the ME population.
Conclusion: The results suggest that the efficacy and safety of ceftazidime-avibactam may be similar to that of imipenem-cilastatin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1185/03007995.2012.748653 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
Eur J Clin Microbiol Infect Dis
December 2024
Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy.
Article Synopsis
- The study investigates how KPC variants of Klebsiella pneumoniae develop resistance to new β-lactam/β-lactamase inhibitor combinations (βL/βLICs) among patients treated with these antibiotics.
- Researchers conducted a case series involving four patients with bloodstream infections linked to KPC-Kp, noting that most had underlying health issues and experienced severe complications.
- Resistance mutations were identified in the KPC genes following treatment, emphasizing that the use of novel βL/βLICs can lead to the emergence of resistant strains, particularly against ceftazidime/avibactam.
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.
Expert Rev Anti Infect Ther
December 2024
Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Türkiye.
Article Synopsis
- * The optimal treatment for certain resistant infections is ceftazidime/avibactam, with other alternatives like imipenem/cilastatin/relebactam and meropenem/vaborbactam serving as backup options, especially for KPC-positive cases.
- * Emerging treatment strategies involve using combinations such as ceftazidime/avibactam with aztreonam for tougher infections, while AI-driven risk models can help predict infection risks in vulnerable patients.
Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing complex and difficult-to-treat resistance (DTR) infections: a single-center preliminary experience.
Front Microbiol
July 2024
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Introduction: Real-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing complex (KPC-Kp) and difficult-to-treat resistance (DTR) (DTR-PA) infections is herein described.
Methods: Adult patients with KPC-Kp or DTR-PA infections who received ≥48 h of IMI/REL were included. Clinical and microbiological outcomes were retrieved through the medical records.
A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Int J Antimicrob Agents
September 2024
Department of Anaesthesiology, Critical Care and Perioperative Medicine, Nancy University Hospital, Nancy, France; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.
Background: Novel beta-lactams show activity against many multidrug-resistant Gram-negative bacteria that cause severe lung infections. Understanding pharmacokinetic/pharmacodynamic characteristics of these agents may help optimise outcomes in the treatment of pneumonia.
Objectives: To describe and appraise studies that report pulmonary pharmacokinetic and pharmacodynamic data of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam and meropenem/vaborbactam.
Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
Ann Intern Med
May 2024
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda; and Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland (J.R.S., A.Mishuk, C.Y.D., A.Mansera, B.J.S., M.W., C.Y., M.N., S.W., S.S.K.).
Background: The U.S. antibiotic market failure has threatened future innovation and supply.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!